1 protein, 2 personalities: Penn team identifies new mechanism of cancer spread

December 11, 2013

Cancer involves a breakdown of normal cell behavior. Cell reproduction and movement go haywire, causing tumors to grow and spread through the body.

A new finding by University of Pennsylvania scientists has identified key steps that trigger this disintegration of cellular regulation. Their discovery--that a protein called Exo70 has a split personality, with one form keeping cells under tight control and another contributing to the ability of tumors to invade distant parts of the body--points to new possibilities for diagnosing cancer spread.

The research, published in the journal Developmental Cell, was conducted by a team comprised of researchers from the School of Arts and Sciences' Department of Biology; the Perelman School of Medicine's pathobiology and laboratory medicine, medicine and genetics departments, and China's Hangzhou Normal University School of Medicine.

"It turns out that one form of Exo70 is important in maintaining 'law and order' in cells, keeping them structured and organized in tissues" said senior author Wei Guo, an associate professor of biology, "while the other form promotes cell movement."

This was not the first time that Guo's group had focused on Exo70, which plays a role in the process known as exocytosis, by which cells transport proteins and other molecules such as hormones and neurotransmitters to the membrane and release them. In previous work, combining biochemistry, ultrastructure cell imaging and mathematical modeling, they showed that Exo70 and a host of other proteins, collectively known as the exocyst, are involved in cell migration, and that Exo70 itself is critical for cell membranes to initiate movement by bending the cell's plasma membrane.

But it turns out that the Exo70 they were studying was only one of five forms present in cells. In the current work, they found that one of these forms was associated with epithelial cells, which line the body's organs and cavities. They called this form Exo70E. The form they had studied in previous work was associated with mesenchymal cells, or cells that are highly motile. They called this form Exo70M.

The fact that these forms associated with epithelial and mesenchymal cells, respectively, caused the researchers to think about a process called the epithelial-mesenchymal transition, or EMT. In it, epithelial cells, which are normally tightly packed together and structured, acquire the ability to migrate. EMT is a normal part of cell biology that occurs in processes such as neural tube formation and wound healing, but also occurs at the beginning of cancer metastasis.

To see what role Exo70 might be playing in EMT, the researchers studied a laboratory cell line in which they could induce EMT. As the transition occurred, they observed that levels of Exo70E declined while Exo70M rose. They found that a protein called epithelial splicing regulatory protein 1, or ESRP1, appeared to play a role in switching between forms, promoting the Exo70E form and preventing EMT from occurring. ERSP1 itself has been shown by Perelman School of Medicine researchers, including Associate Professor of Medicine Russ Carstens, to be a major regulator in EMT.

Experimenting further to investigate how the two forms of Exo70 affected cell behavior, the team found that adding Exo70E to mesenchymal cells caused them to look more like epithelial cells, retaining structure and inhibiting movement. When they inhibited all forms of Exo70 in a line of breast cancer cells, the tumor cells lost their ability to migrate, a necessary part of tumor invasion. Adding back Exo70M, however, allowed these cells to regain their ability to migrate and invade, while Exo70E did not.

These results were upheld in experiments in mice. The researchers inoculated the mice with breast cancer cells that had been genetically engineered to express either Exo70E or Exo70M. Normally, the cancerous cells would spread all around the body and indeed, this is what the researchers saw in the mice exposed to the cells with the Exo70M form. But there was no evidence of such metastasis in mice given cells expressing only Exo70E.

"In this case, Exo70E was behaving almost like a tumor suppressor," Guo said.

Finally, to see if their findings would be clinically relevant in humans, the researchers looked for the different forms of Exo70 in tissue from human breast cancer patients.

"We found that patients who had a high E-to-M form ratio had cancers that were less likely to have spread," Guo said. "Patients who had cancers that spread to the lymph nodes had more of the M form."

Such a finding offers a potential biomarker for clinicians to judge the progression of cancers, or the likelihood of a particular case of cancer to spread.
-end-
In addition to Guo, the paper authors included Penn's Hezhe Lu, Jianglan Liu and Jingwen Zeng of the Department of Biology, Shujing Liu and Xiaowei Xu of the Department of Pathobiology and Laboratory Medicine, and Russ Carstens of the departments of Medicine and Genetics. They collaborated with Dequiang Ding and Yusheng Cong of the Institute of Aging Research at China's Hangzhou Normal University of Medicine.

The research was supported by the National Institutes of Health.

University of Pennsylvania

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.